asymptomatic diabetic patient
Recently Published Documents


TOTAL DOCUMENTS

6
(FIVE YEARS 0)

H-INDEX

2
(FIVE YEARS 0)

2016 ◽  
Vol 9 (2) ◽  
pp. 176-192 ◽  
Author(s):  
Matthew J. Budoff ◽  
Paolo Raggi ◽  
George A. Beller ◽  
Daniel S. Berman ◽  
Regina S. Druz ◽  
...  

2015 ◽  
Vol 23 (1) ◽  
pp. 37-41 ◽  
Author(s):  
Daniel S. Berman ◽  
Matthew J. Budoff ◽  
James K. Min ◽  
Paolo Raggi ◽  
Alan Rozanski ◽  
...  

2010 ◽  
Vol 7 (1) ◽  
pp. 76-80
Author(s):  
Dimitrios Bliagos ◽  
Ajay J Kirtane ◽  
Jeffrey W Moses ◽  
◽  
◽  
...  


2010 ◽  
Vol 6 (1) ◽  
pp. 62
Author(s):  
Dimitrios Bliagos ◽  
Ajay J Kirtane ◽  
Jeffrey W Moses ◽  
◽  
◽  
...  

In the US, a total of 23.6 million people have diabetes, representing 7.8% of the population, and the prevalence of diabetes is on the rise due to an increasingly sedentary lifestyle, increasing obesity and an ageing population. Coronary artery disease is the leading cause of death in patients with diabetes, despite a reduction in cardiovascular events over the last 50 years, due in part to better medical therapy. Asymptomatic diabetic patients with evidence of ischaemia on stress testing have higher cardiac mortality; increasing amounts of ischaemia are associated with higher mortality rates. Revascularisation of high-risk patients, or those with significant ischaemia, has the potential to improve outcomes in this patient population. The choice of which revascularisation strategy to choose – either percutaneous coronary intervention (PCI) or coronary artery bypass grafting – should be carefully individualised, and must always be implemented against the background of optimal medical therapy.


Sign in / Sign up

Export Citation Format

Share Document